OpenEvidence enters drug development with a unique physician distribution edge
dr_alphalyrae · x · 2026-09-23
Commentator Patrick Malone notes OpenEvidence is getting into drug development, under-discussed so far. Its edge: physicians actively consult the platform at the moment of treatment decisions. This relaxes two drug-development constraints — clinical complexity doctors must remember, and the market size needed to support commercial infrastructure, since OE can spread engagement costs across many drugs via one platform.
More from Companies & People
- OpenAI pledges deep third-party access to training, evals and deployment for independent safety audits — OpenAI · 2026-09-23
- PyMC Labs hosts Oct 2 panel on agentic data science with scikit-learn co-creator — twiecki · 2026-09-23
- Survey ranks data companies for aspiring founders: Mercor tops with 13 votes, Anthropic data team gets 2 — herbiebradley · 2026-09-23
- Richard Socher's The Eureka Machine argues AI will deliver a century of breakthroughs in a decade — RichardSocher · 2026-09-23
- MIT ranks #1 among National Universities for the first time — ProfBuehlerMIT · 2026-09-23
- SemiAnalysis' Dylan Patel: Chinese labs going closed-source, 'open is dying quickly' — Sentdex · 2026-09-23